{"id":325,"date":"2023-02-14T12:31:35","date_gmt":"2023-02-14T12:31:35","guid":{"rendered":"https:\/\/amiratx.com\/?page_id=325"},"modified":"2024-07-26T10:59:12","modified_gmt":"2024-07-26T10:59:12","slug":"candidates","status":"publish","type":"page","link":"https:\/\/amiratx.com\/index.php\/candidates\/","title":{"rendered":"Pipeline"},"content":{"rendered":"

[et_pb_section fb_built=”1″ module_id=”menu” _builder_version=”4.19.5″ _module_preset=”3e9a3862-c027-4e18-a226-3bd89ec0ffbe” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” min_height=”111px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” border_color_all=”#81b949″ global_colors_info=”{}”][et_pb_text _builder_version=”4.19.5″ _module_preset=”default” min_height=”63px” global_colors_info=”{}”]<\/p>\n

Our lead candidate, AMI463, has received Orphan Drug Designation from the European Medicines Agency (EMA) and from the U.S. Food and Drug Administration (FDA) for the treatment of Soft-Tissue Sarcoma (STS). We are currently advancing its development for Rhabdomyosarcoma (RMS), a rare and challenging cancer predominantly found in soft tissues like skeletal muscle or occasionally in hollow organs, indication for which AMI463 has obtained the Rare Pediatric Disease Designation (RPDD) from the FDA. This development underscores our commitment to addressing areas of significant unmet medical need. Furthermore, we recognize the broader potential of AMI463 in treating various forms of soft-tissue sarcoma and other solid tumors in both pediatric and adult patients.<\/span><\/p>\n

[\/et_pb_text][et_pb_divider color=”#00a2db” divider_style=”dotted” divider_position=”bottom” divider_weight=”1px” _builder_version=”4.16″ _module_preset=”default” custom_margin=”19px||-1px||false|false” global_colors_info=”{%22gcid-69ff89f1-8a2c-4db1-9255-07c8d2fdc3b6%22:%91%22color%22%93,%22gcid-f3597255-bbe1-4565-b3bd-30252c3e5dfd%22:%91%93,%22gcid-0cd125cc-2fb9-4f8e-800c-2fd7c0698e37%22:%91%93}”][\/et_pb_divider][et_pb_text _builder_version=”4.19.5″ _module_preset=”default” header_3_font=”Roboto||||||||” header_3_text_color=”#00a2db” header_3_line_height=”1.3em” custom_margin=”||-10px|||” custom_padding=”4px||0px|||” border_color_all=”#81b949″ border_style_all=”none” border_width_bottom=”2px” border_color_bottom=”#2ea3f2″ global_colors_info=”{%22gcid-69ff89f1-8a2c-4db1-9255-07c8d2fdc3b6%22:%91%22header_3_text_color%22%93,%22gcid-e4398102-3122-4a9c-829d-8a0ecf485005%22:%91%93}”]<\/p>\n

 <\/p>\n

Our Pipeline<\/span><\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_6,1_6,1_6,1_6,1_6,1_6″ disabled_on=”on|off|off” _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_6″ disabled_on=”on|off|off” _builder_version=”4.19.5″ _module_preset=”default” display_conditions=”W10=” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Candidate<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Indication<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Preclinical<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Phase 1<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” custom_margin=”|||0px|false|false” custom_padding=”|||0px|false|false” global_colors_info=”{}”]<\/p>\n

Phase 2\/3 (PoC)<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

NDA\/MAA<\/strong><\/h6>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_5,1_5,3_5″ _builder_version=”4.16″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” border_width_top=”1px” border_color_top=”#f7f7f7″ border_width_bottom=”1px” border_color_bottom=”#f7f7f7″ locked=”off” global_colors_info=”{}”][et_pb_column type=”1_5″ _builder_version=”4.16″ custom_padding=”0px||0px||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.5″ _dynamic_attributes=”link_option_url” _module_preset=”default” text_text_color=”#f37c3e” custom_margin=”10px||||false|false” link_option_url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjE0MSJ9fQ==@” global_colors_info=”{}”]<\/p>\n

AMI463<\/span><\/h5>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_5″ _builder_version=”4.16″ custom_padding=”0px||0px||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.17.4″ _module_preset=”default” custom_margin=”10px||||false|false” global_colors_info=”{}”]<\/p>\n

Pediatric RMS – Rhabdomyosarcoma<\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_counters bar_bg_color=”#8300E9″ _builder_version=”4.19.5″ _module_preset=”default” background_color=”#cccccc” width=”102.3956194387406%” custom_margin=”||25px|-14px|false|false” custom_padding=”|||0px|false|false” global_colors_info=”{}”][et_pb_counter percent=”25″ bar_background_color=”#ee4f39″ _builder_version=”4.19.5″ _module_preset=”default” title_font_size=”10px” percent_text_color=”#ee4f39″ background_color=”#efefef” background_enable_color=”on” background_enable_video_mp4=”on” background_enable_video_webm=”on” global_colors_info=”{}” bar_background_color_default=”#8300E9″ use_percentages=”on”]Preclinical – Novel CDO inhibitor (in collaboration with Vall d’Hebron Institute of Research) – initiating IND enabling studies[\/et_pb_counter][\/et_pb_counters][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_5,1_5,3_5″ _builder_version=”4.16″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” border_width_top=”1px” border_color_top=”#f7f7f7″ border_width_bottom=”1px” border_color_bottom=”#f7f7f7″ locked=”off” global_colors_info=”{}”][et_pb_column type=”1_5″ _builder_version=”4.16″ custom_padding=”0px||0px||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.5″ _module_preset=”default” custom_margin=”10px||||false|false” global_colors_info=”{}”]<\/p>\n

AMI605<\/span><\/h5>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_5″ _builder_version=”4.16″ custom_padding=”0px||0px||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” custom_margin=”10px||||false|false” global_colors_info=”{}”]<\/p>\n

Pediatric Glioblastoma and CNS tumors<\/h6>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_counters bar_bg_color=”#ee4f39″ _builder_version=”4.19.5″ _module_preset=”default” title_font_size=”10px” percent_text_color=”#ee4f39″ width=”102.3956194387406%” custom_margin=”||25px|-14px|false|false” custom_padding=”|||0px|false|false” global_colors_info=”{}”][et_pb_counter percent=”22″ bar_background_color=”#ee4f39″ _builder_version=”4.19.5″ _module_preset=”default” percent_text_color=”#ee4f39″ background_color=”#efefef” background_enable_color=”on” background_enable_video_mp4=”on” background_enable_video_webm=”on” global_colors_info=”{}” bar_background_color_default=”#ee4f39″ use_percentages=”on”]Preclinical – Novel RCAN1 inhibitor – Completing in-vivo efficacy studies[\/et_pb_counter][\/et_pb_counters][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Our lead candidate, AMI463, has received Orphan Drug Designation from the European Medicines Agency (EMA) and from the U.S. Food and Drug Administration (FDA) for the treatment of Soft-Tissue Sarcoma (STS). We are currently advancing its development for Rhabdomyosarcoma (RMS), a rare and challenging cancer predominantly found in soft tissues like skeletal muscle or occasionally […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-325","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/pages\/325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/comments?post=325"}],"version-history":[{"count":8,"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/pages\/325\/revisions"}],"predecessor-version":[{"id":604,"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/pages\/325\/revisions\/604"}],"wp:attachment":[{"href":"https:\/\/amiratx.com\/index.php\/wp-json\/wp\/v2\/media?parent=325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}